> GeNeuro posted 12-month data from its Servier-partnered multiple sclerosis phase 2b. The trial missed its primary endpoint last year, but since then the partners have posted data they think support discussions about further development of the asset. Statement
> Shares in Verona Pharma climbed after the company posted data from a phase 2b trial of RPL554 in COPD. The trial linked the dual inhibitor of the phosphodiesterase 3 and 4 to statistically significant improvements in lung function. Release
> DBV Technologies sold all the additional shares in its global offering, bringing its total gross haul up to $172.5 million (€140.8 million). Statement
> Summit Therapeutics raised £15 million ($21 million). The money will support further development of ezutromid in Duchenne muscular dystrophy. Release
> Auris Medical regained compliance with Nasdaq’s minimum bid price requirement. Statement